Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

HDHaiping DaiDWDepei WuSCSuning Chen

Discussion

Loading...

Member takes

Overview

Prospective trial shows improved survival rates in newly diagnosed IDH1-mutant AML with venetoclax and azacitidine.

Key Points

  • To investigate the efficacy and safety of Ivosidenib combined with Venetoclax and Azacitidine in newly diagnosed IDH1-mutant Acute Myeloid Leukemia.
  • Prospective, single-arm, dual-cohort, multi-center study
  • Enrolled 42 patients with IDH1 mutations in two cohorts
  • Utilized survival rate and complete remission rates as primary endpoints
  • Survival rate reached 71% in newly diagnosed AML patients
  • Combined treatment shows good tolerability and efficacy
  • Aims to clarify feasibility of multi-drug regimens in IDH1-mutant AML patients

Cite This Study

Dai et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1dchttps://doi.org/10.1182/blood-2025-8249
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in <i>IDH1</i> -mutated acute myeloid leukemia (AML).2026
  2. 2A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress2025
  3. 3Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)2025 · 3 citations
  4. 4Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis2025 · 1 citations
  5. 5Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation2025 · 2 citations